Literature DB >> 20148655

Sustained subconjunctival protein delivery using a thermosetting gel delivery system.

Erin R Rieke1, Juan Amaral, S Patricia Becerra, Robert J Lutz.   

Abstract

PURPOSE: An effective treatment modality for posterior eye diseases would provide prolonged delivery of therapeutic agents, including macromolecules, to eye tissues using a safe and minimally invasive method. The goal of this study was to assess the ability of a thermosetting gel to deliver a fluorescently labeled protein, Alexa 647 ovalbumin, to the choroid and retina of rats following a single subconjunctival injection of the gel. Additional experiments were performed to compare in vitro to in vivo ovalbumin release rates from the gel.
METHODS: The ovalbumin content of the eye tissues was monitored by spectrophotometric assays of tissue extracts of Alexa 647 ovalbumin from dissected sclera, choroid, and retina at time points ranging from 2 h to 14 days. At the same time points, fluorescence microscopy images of tissue samples were also obtained. Measurement of intact ovalbumin was verified by LDS-PAGE analysis of the tissue extract solutions. In vitro release of Alexa 488 ovalbumin into 37 degrees C PBS solutions from ovalbumin-loaded gel pellets was also monitored over time by spectrophotometric assay. In vivo ovalbumin release rates were determined by measurement of residual ovalbumin extracted from gel pellets removed from rat eyes at various time intervals.
RESULTS: Our results indicate that ovalbumin concentrations can be maintained at measurable levels in the sclera, choroid, and retina of rats for up to 14 days using the thermosetting gel delivery system. The concentration of ovalbumin exhibited a gradient that decreased from sclera to choroid and to retina. The in vitro release rate profiles were similar to the in vivo release profiles.
CONCLUSIONS: Our findings suggest that the thermosetting gel system may be a feasible method for safe and convenient sustained delivery of proteins to choroidal and retinal tissue in the posterior segments of the eye.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20148655      PMCID: PMC3096542          DOI: 10.1089/jop.2009.0059

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  27 in total

Review 1.  Drug delivery for posterior segment eye disease.

Authors:  D H Geroski; H F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-04       Impact factor: 4.799

Review 2.  Drug delivery to the retina: challenges and opportunities.

Authors:  Sridhar Duvvuri; Soumyajit Majumdar; Ashim K Mitra
Journal:  Expert Opin Biol Ther       Date:  2003-02       Impact factor: 4.388

3.  Age-related macular degeneration is the leading cause of blindness...

Authors:  Neil M Bressler
Journal:  JAMA       Date:  2004-04-21       Impact factor: 56.272

4.  A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres.

Authors:  Hong Li; Veronique V Tran; Yueyue Hu; W Mark Saltzman; Colin J Barnstable; Joyce Tombran-Tink
Journal:  Exp Eye Res       Date:  2006-07-05       Impact factor: 3.467

5.  Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis.

Authors:  E Sakurai; Y Matsuda; H Ozeki; N Kunou; K Nakajima; Y Ogura
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-08       Impact factor: 4.799

6.  Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.

Authors:  G J Jaffe; C H Yang; H Guo; J P Denny; C Lima; P Ashton
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

7.  Biodegradable block copolymers for delivery of proteins and water-insoluble drugs.

Authors:  G M Zentner; R Rathi; C Shih; J C McRea; M H Seo; H Oh; B G Rhee; J Mestecky; Z Moldoveanu; M Morgan; S Weitman
Journal:  J Control Release       Date:  2001-05-14       Impact factor: 9.776

8.  Prevalence of age-related macular degeneration in the United States.

Authors:  David S Friedman; Benita J O'Colmain; Beatriz Muñoz; Sandra C Tomany; Cathy McCarty; Paulus T V M de Jong; Barbara Nemesure; Paul Mitchell; John Kempen
Journal:  Arch Ophthalmol       Date:  2004-04

9.  Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761.

Authors:  Yingli Fu; M Lourdes Ponce; Michelle Thill; Peng Yuan; Nam Sun Wang; Karl G Csaky
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

10.  Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.

Authors:  Aki Kato; Hideya Kimura; Komei Okabe; Junko Okabe; Noriyuki Kunou; Yuichiro Ogura
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-01       Impact factor: 4.799

View more
  10 in total

1.  Biodegradable Thermosensitive PLGA-PEG-PLGA Polymer for Non-irritating and Sustained Ophthalmic Drug Delivery.

Authors:  Pui Shan Chan; Jia Wen Xian; Qingqing Li; Chun Wai Chan; Sharon S Y Leung; Kenneth K W To
Journal:  AAPS J       Date:  2019-04-24       Impact factor: 4.009

Review 2.  Nanotechnology in retinal drug delivery.

Authors:  Sibo Jiang; Yesenia L Franco; Yan Zhou; Jianjun Chen
Journal:  Int J Ophthalmol       Date:  2018-06-18       Impact factor: 1.779

3.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

4.  Subconjunctival injectable dendrimer-dexamethasone gel for the treatment of corneal inflammation.

Authors:  Uri Soiberman; Siva P Kambhampati; Tony Wu; Manoj K Mishra; Yumin Oh; Rishi Sharma; Jiangxia Wang; Abdul Elah Al Towerki; Samuel Yiu; Walter J Stark; Rangaramanujam M Kannan
Journal:  Biomaterials       Date:  2017-02-16       Impact factor: 12.479

Review 5.  Recent advances in ophthalmic drug delivery.

Authors:  Uday B Kompella; Rajendra S Kadam; Vincent H L Lee
Journal:  Ther Deliv       Date:  2010-09

Review 6.  Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives.

Authors:  Hyeong Min Kim; Se Joon Woo
Journal:  Pharmaceutics       Date:  2021-01-15       Impact factor: 6.321

Review 7.  Advanced biomedical hydrogels: molecular architecture and its impact on medical applications.

Authors:  Jonathan T Peters; Marissa E Wechsler; Nicholas A Peppas
Journal:  Regen Biomater       Date:  2021-11-09

Review 8.  Delivery Systems of Retinoprotective Proteins in the Retina.

Authors:  Ivan T Rebustini; Alexandra Bernardo-Colón; Alejandra Isasi Nalvarte; S Patricia Becerra
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

Review 9.  Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.

Authors:  Eliana B Souto; João Dias-Ferreira; Ana López-Machado; Miren Ettcheto; Amanda Cano; Antonio Camins Espuny; Marta Espina; Maria Luisa Garcia; Elena Sánchez-López
Journal:  Pharmaceutics       Date:  2019-09-06       Impact factor: 6.321

10.  Sustained-release voriconazole-thermogel for subconjunctival injection in horses: ocular toxicity and in-vivo studies.

Authors:  Mariano Mora-Pereira; Eva M Abarca; Sue Duran; William Ravis; Richard J McMullen; Britta M Fischer; Yann-Huei Phillip Lee; Anne A Wooldridge
Journal:  BMC Vet Res       Date:  2020-04-16       Impact factor: 2.741

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.